Ocugen Inc
(NASDAQ: OCGN)

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

1.335 -

-0.055 (-3.96%)
价格区间 1.310 - 1.400   (6.87%)
开盘 1.390
昨收 1.390
1.330
买盘 54,320
1.340
卖盘 15,914
成交量 5,093,215
成交额 4,325,647
注释 -
数据延迟。最后一次更新19 May 2026 03:10.
数据提供商
查看所有活动


Loading Chart...

Please login to view stock data and analysis